United States· US:87628-101_d8cdbc6a-e494-41e5-afde-7863dd452b9c
Varubi
A rolapitant product containing rolapitant hydrochloride, registered in United States by Luria Therapeutics LLC. The same ATC class is registered in 4 of our 19 countries.
Checked against FDA National Drug Code directory (United States) on
Informational only — not a medical device.
Where it is registered
Rolapitant is registered in 4 of 19 countries.
Countries holding a registration under ATC A04AD14 (rolapitant), each read from that country’s own register.
- This record: United States, from FDA National Drug Code directory (United States)
- 3 of them publish a price we can compare per daily dose
Rolapitant · ATC A04AD14
4 / 19 countries
- Belgiumprice
- Finlandprice
- United Kingdom
- United Statesprice
The record
At a glance
FDA National Drug Code directory (United States)- Active substance
- ROLAPITANT HYDROCHLORIDE
- Manufacturer
- Luria Therapeutics LLC
- Country
- United States (US)
- ATC code
- A04AD14
- ATC class
- Rolapitant
- Defined daily dose
- 0.18 g, O
- Reimbursed
- Not published by this register
- Source register
- FDA National Drug Code directory (United States)
- Last checked
- September 6, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
240 interactions on record for rolapitant.
Graded by severity as the source publishes them — 26 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Rolapitant · interactions on record
240 records
- 26 severe
- 207 moderate
- 7 minor
Most severe, free to view
- EliglustatA16AX10severe
- EdoxabanB01AF03severe
- BetrixabanB01AF04severe
- BerotralstatB06AC06severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Rolapitant in 3 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FDA National Drug Code directory (United States). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/33a2babe-7339-404f-a8ce-348f476f21c5 GET /v1/drugs/33a2babe-7339-404f-a8ce-348f476f21c5?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"route": "ORAL",
"source": "ndc",
"strength": "90",
"substance": "ROLAPITANT HYDROCHLORIDE",
"productndc": "87628-101",
"dosage_form": "TABLET",
"dea_schedule": null,
"strength_unit": "mg/1",
"application_number": "NDA206500",
"marketing_category": "NDA"
}See everything about rolapitant.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.